EXOME: Biotech • Healthcare • Life Sciences

National
Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More

Boston
New Webinars: Simple Signaling Reporter Assays & Reducing Attrition From Drug-Induced Liver Injury
San Francisco
Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact
New York
Merck Outlines COVID-19 Ambitions With Buyout Deal, Collaborations

1.
Forma Therapeutics Eyes IPO to Advance Sickle Cell, Prostate Cancer Drugs | Boston
2.
After Inking Bristol Myers Pact, Repare Therapeutics Sets Sights on IPO | Boston
3.
AbbVie Wins First FDA Approval of Drug to Treat Uterine Fibroid Bleeds | National
4.
Bio Roundup: ASCO Opens, Merck Takes On COVID, Evofem’s Approval & More | National
5.
Variant Emerges With $16M to Find “Outlier Humans” to Reveal New Drugs | Seattle
6.
FDA Welcomes Variety of Phase 2/3 Trial Designs for COVID-19 Therapies | National

Learn about the Xconomists →

Alexis Peyroles

Creating Consistent Value in Biotech Without Diluting Stakeholders

Andy Smith

Lax Approval Requirements Yield Blockbusters That Don’t Work

More Opinion, Insight, and Analysis ›

Xcelerating Life Sciences Seattle

October 1, 2020

$375M

Gilead Sciences/Arcus Biosciences

Ipsen Taps Sanofi’s Vaccines Executive David Loew for CEO Role

Flagship Pioneering Taps Chouraqui as CEO-Partner, CEO of Cellarity

AbCellera Raises $105M to Advance Antibody Discovery Operations
Sarah de Crescenzo | Seattle
New Webinars: Simple Signaling Reporter Assays & Reducing Attrition From Drug-Induced Liver Injury
Editors | Boston
Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact
Frank Vinluan | San Francisco
Merck Outlines COVID-19 Ambitions With Buyout Deal, Collaborations
Sarah de Crescenzo | New York
Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development
Sarah de Crescenzo | San Francisco
Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments
Sarah de Crescenzo | San Diego
COVID-19 Sparks New Opportunities for Digital Health Companies
Frank Vinluan | Boston
Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq
Frank Vinluan | National
FDA Approves Evofem’s “On-Demand” Non-Hormonal Birth Control Gel
Sarah de Crescenzo | National

Read More Posts ›

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
Decentralized Clinical Trials: The Call for a New Paradigm
Virtual/hybrid trials and decentralized research can better integrate healthcare into patients’ lives and accelerate approval of new medications
PRA Health Sciences

Sponsored · Webinar
Screening Approaches for Reducing Attrition Due to Drug-induced Liver Injury (DILI) Early in Drug Discovery
In vitro assays that tackle the challenges of in vitro hepatotoxicity assessment
Eurofins Discovery

From Our Editors · Podcast
Xcelerating Life Sciences San Diego: The Highlights Podcast
Learn what's fueling San Diego's biotech investment and partnership opportunities

Xconomy on Demand

We offer a number of ways to subscribe for free!